Resistance to 5-fluorouracilMADER, R. M; MÜLLER, M; STEGER, G. G et al.General pharmacology. 1998, Vol 31, Num 5, pp 661-666, issn 0306-3623Article

Efficacy of tamoxifen + aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trialPFEILER, G; STÖGER, H; RENNER, K et al.British journal of cancer. 2013, Vol 108, Num 7, pp 1408-1414, issn 0007-0920, 7 p.Article

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters : final results of a double-blind, placebo-controlled phase III trialKARTHAUS, M; KRETZSCHMAR, A; BARONIUS, W et al.Annals of oncology. 2006, Vol 17, Num 2, pp 289-296, issn 0923-7534, 8 p.Article

The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinomaSTEGER, G. G; KABOO, R; DEKERNION, J. B et al.British journal of cancer. 1995, Vol 72, Num 1, pp 101-107, issn 0007-0920Article

Comparison of an immunoradiometric and an immunoluminometric assay for the evaluation of the tumour associated antigens CA 19-9 and CA 125MADER, R. M; STEGER, G. G; BRAUN, J et al.European journal of clinical chemistry and clinical biochemistry. 1994, Vol 32, Num 2, pp 85-90, issn 0939-4974Article

Double modulation of 5-fluorouracil by high-dose leucovorin and interferon α2b in advanced colorectal cancer : a phase I and a phase II study of weekly administrationSTEGER, G. G; MADER, R. M; DJAVANMARD, M. P et al.Journal of cancer research and clinical oncology. 1994, Vol 120, Num 5, pp 314-318, issn 0171-5216Article

GM-CSF in the treatment of a patient with severe methotrexate intoxicationSTEGER, G. G; MADER, R. M; GNANT, M. F. X et al.Journal of internal medicine. 1993, Vol 233, Num 6, pp 499-502, issn 0954-6820Article

Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case seriesZAGOURI, F; SERGENTANIS, T. N; BARTSCH, R et al.British journal of cancer. 2013, Vol 108, Num 11, pp 2259-2263, issn 0007-0920, 5 p.Article

Gene expression profiling of colon cancer reveals a broad molecular repertoire in 5-fluorouracil resistanceSCHMIDT, W. M; KALIPCIYAN, M; DORNSTAUDER, E et al.International journal of clinical pharmacology and therapeutics. 2003, Vol 41, Num 12, pp 624-625, issn 0946-1965, 2 p.Article

Interstitial methotrexate kinetics in primary breast cancer lesionsMÜLLER, M; BRUNNER, M; SCHMID, R et al.Cancer research (Baltimore). 1998, Vol 58, Num 14, pp 2982-2985, issn 0008-5472Article

5-Fluorouracil kinetics in the interstitial tumor space : Clinical response in breast cancer patientsMÜLLER, M; MADER, R. M; STEINER, B et al.Cancer research (Baltimore). 1997, Vol 57, Num 13, pp 2598-2601, issn 0008-5472Article

Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancerMADER, R. M; ZILG, H; SCHLAPPACK, O et al.Cancer chemotherapy and pharmacology. 1995, Vol 37, Num 1-2, pp 91-96, issn 0344-5704Article

Folate absorption in Crohn's diseaseSTEGER, G. G; MADER, R. M; VOGELSANG, H et al.Digestion. 1994, Vol 55, Num 4, pp 234-238, issn 0012-2823Article

Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL) : evidence for enhanced specific killing of tumor necrosis factor-secreting/Il-6 nonsecreting TIL in vitro and correlation with complete response in vivoSTEGER, G. G; PIERCE, W. C; FIGLIN, R et al.Clinical immunology and immunopathology (Print). 1994, Vol 72, Num 2, pp 237-247, issn 0090-1229Article

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastasesBARTSCH, R; BERGHOFF, A; MADER, R. M et al.British journal of cancer. 2012, Vol 106, Num 1, pp 25-31, issn 0007-0920, 7 p.Article

Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer : A single-centre experienceSTEGER, G. G; BARTSCH, R; WENZEL, C et al.European journal of cancer (1990). 2005, Vol 41, Num 17, pp 2655-2661, issn 0959-8049, 7 p.Article

Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancerMADER, R. M; SCHROLNBERGER, C; RIZOVSKI, B et al.British journal of cancer. 2003, Vol 88, Num 5, pp 782-787, issn 0007-0920, 6 p.Article

Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF : results of a prospective randomised trialHEJNA, M; KÖSTLER, W. J; RADERER, M et al.European journal of cancer (1990). 2001, Vol 37, Num 16, pp 1994-2002, issn 0959-8049Article

The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinomaSTEGER, G. G; GNANT, M. F; DJAVANMARD, M. P et al.Journal of cancer research and clinical oncology. 1997, Vol 123, Num 6, pp 317-324, issn 0171-5216Article

Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azidothymidineFINDENIG, G; MADER, R. M; FRITZER-SZEKERES, M et al.Oncology research. 1996, Vol 8, Num 5, pp 189-196, issn 0965-0407Article

Instability of the anticancer agent etoposide under in vitro culture conditionsMADER, R. M; STEGER, G. G; MOSER, K et al.Cancer chemotherapy and pharmacology. 1991, Vol 27, Num 5, pp 354-360, issn 0344-5704, 7 p.Article

Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancerSTEGER, G. G; DITTRICH, C; SCHLAPPACK, O et al.Journal of cancer research and clinical oncology. 1988, Vol 114, Num 6, pp 602-604, issn 0171-5216Article

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)STEGER, G. G; GREIL, R; STOEGER, H et al.Annals of oncology. 2014, Vol 25, Num 2, pp 366-371, issn 0923-7534, 6 p.Article

Brain metastases free survival differs between breast cancer subtypesBERGHOFF, A; BAGO-HORVATH, Z; DIECKMANN, K et al.British journal of cancer. 2012, Vol 106, Num 3, pp 440-446, issn 0007-0920, 7 p.Article

Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancerSCHMIDT, M; RÜTTINGER, D; STEGER, G. G et al.Annals of oncology. 2012, Vol 23, Num 9, pp 2306-2313, issn 0923-7534, 8 p.Article